Related Experiment Video

Updated: Jan 30, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

2.9K

HIV-1 escape in the central nervous system on elvitegravir-based antiretroviral therapy

Claire Guerveno1, Stéphanie Raymond2,3, David Metsu4,5

  • 1CHU de Toulouse, Service des Maladies Infectieuses et Tropicales.

AIDS (London, England)
|February 1, 2019
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Genotypic Inference of HIV-1 Tropism Using Population-based Sequencing of V3
11:10

Genotypic Inference of HIV-1 Tropism Using Population-based Sequencing of V3

Published on: December 27, 2010

12.8K
Lumbar Intrathecal Injection of Gene Therapy Vectors for Central Nervous System Targeting in Mice and Rats
05:09

Lumbar Intrathecal Injection of Gene Therapy Vectors for Central Nervous System Targeting in Mice and Rats

Published on: May 16, 2025

3.2K

Related Experiment Videos

Last Updated: Jan 30, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

2.9K
Genotypic Inference of HIV-1 Tropism Using Population-based Sequencing of V3
11:10

Genotypic Inference of HIV-1 Tropism Using Population-based Sequencing of V3

Published on: December 27, 2010

12.8K
Lumbar Intrathecal Injection of Gene Therapy Vectors for Central Nervous System Targeting in Mice and Rats
05:09

Lumbar Intrathecal Injection of Gene Therapy Vectors for Central Nervous System Targeting in Mice and Rats

Published on: May 16, 2025

3.2K

Related Concept Videos

What is a Nervous System?01:25

What is a Nervous System?

104.6K
Overview
104.6K
Escape Velocity01:26

Escape Velocity

8.4K
The escape velocity of an object is defined as the minimum initial velocity that it requires to escape the surface of another object to which it is gravitationally bound and never to return. For example, what would be the minimum velocity at which a satellite should be launched from the Earth's surface such that it just escapes the Earth's gravitational field?
To calculate the escape velocity, it is assumed that no energy is lost to any frictional forces. In practice, a satellite...
8.4K
The Parasympathetic Nervous System01:14

The Parasympathetic Nervous System

115.3K
Overview
115.3K
The Sympathetic Nervous System01:25

The Sympathetic Nervous System

103.5K
Overview
103.5K
The Central Dogma01:25

The Central Dogma

139.7K
Overview
139.7K
Escape Velocities of Gases01:19

Escape Velocities of Gases

1.4K
To escape the Earth's gravity, an object near the top of the atmosphere at an altitude of 100 km must travel away from Earth at 11.1 km/s. This speed is called the escape velocity. The temperature at which gas molecules attain the rms speed, which is equal to the escape velocity, can be estimated by using the equation for the average kinetic energy of the gas molecules. According to the kinetic theory of gas, the average kinetic energy of the gas molecules is proportional to its...
1.4K

Articles linked to this work by shared authors, journal, and citation graph.

Neurological Manifestations of Mycoplasma pneumoniae Infection in Hospitalized Adults During the 2023-2024 French Epidemic, Clinical Characterization and Comparative Outcomes: A Multicenter Study.

Open forum infectious diseases·2026

Long-term prognosis of patients surviving progressive multifocal leukoencephalopathy.

Brain : a journal of neurology·2026

Bispecific antibody therapy in multiple myeloma and risk of progressive multifocal leukoencephalopathy.

Blood advances·2026

Polyomavirus-Specific T Cells in Progressive Multifocal Leukoencephalopathy: A Multicenter Retrospective Analysis.

Transplantation and cellular therapy·2026

Prediction of bloodstream infection using triage variables in the emergency department: retrospective derivation and validation cohort.

Emergency medicine journal : EMJ·2026

Emerging evidence for anti-PD-1 and IFN-γ as adjunctive immunotherapy in invasive mold infections.

mBio·2026

HIV-associated pulmonary arterial hypertension: improving survival despite persistent treatment gaps - a systematic review and meta-analysis.

AIDS (London, England)·2026

Real-life durability and virological outcomes of doravirine in people with multidrug-resistant HIV.

AIDS (London, England)·2026

Retention in care: is it still a clinically useful indicator for monitoring long-term engagement in HIV care in the treat-all era?

AIDS (London, England)·2026

Cancer incidence and risk factors among people with HIV in REPRIEVE.

AIDS (London, England)·2026

Effects of semaglutide on subclinical cardiovascular health in people with HIV.

AIDS (London, England)·2026

Antiretroviral therapy regimens initiated during pregnancy and risks of adverse perinatal outcomes.

AIDS (London, England)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us